Here, we found that Gal-1 is largely responsible for NRP1-driven melanoma resistance to therapy and that its targeting with a small molecule inhibitor complemented the effect of NRP1-blockers aimed at resuming drug sensitivity. This evidence concerns the gene NRP1 and melanoma.